Drug Trial Radar · NCT00092040
A Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis (MK-0217-907)
Last checked: Nov 20, 2026Latest source record: Aug 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
936
Actual
Start
Mar 18, 2003
Primary completion
Oct 18, 2004
Study completion Sep 28, 2005
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Sep 24, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study and 12 month extension is to evaluate the effects of two investigational drugs on osteoporosis in postmenopausal women.
Conditions
- Osteoporosis, Postmenopausal
Interventions
MK0217, alendronate sodium/Duration of Intervention: 12 moDrug
Comparator: risedronate / Duration of Intervention: 12 moDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean percent change from baseline in hip trochanter bone mineral density (BMD)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.